5 big analyst AI moves: Nvidia guidance warning; Snowflake, Palo Alto upgraded
Theresa Heggie, a director at BioCryst Pharmaceuticals Inc (NASDAQ:BCRX), a biotech company with a market capitalization of $1.77 billion and impressive revenue growth of 46% over the last twelve months, sold 70,000 shares of common stock on August 13, 2025, for a total of $595,868. The price per share for the sale was $8.5124, close to the current trading price of $8.45. According to InvestingPro analysis, the stock appears slightly undervalued based on its Fair Value estimate.
On the same day, Heggie also exercised options to acquire a total of 70,000 shares of BioCryst common stock. These transactions involved two separate option grants. The first was for 30,000 shares at an exercise price of $2.91, and the second was for 40,000 shares at an exercise price of $5.41, resulting in a total value of $303,700.
Following these transactions, Heggie directly owns 65,352 shares of BioCryst Pharmaceuticals Inc.
In other recent news, BioCryst Pharmaceuticals Inc. reported a significant earnings beat for the second quarter of 2025. The company achieved earnings per share of $0.15, far exceeding the forecasted $0.01, which represents a 1400% surprise. Additionally, BioCryst’s revenue reached $163.4 million, surpassing expectations of $149.82 million. These financial results highlight the company’s strong performance during the quarter. In other developments, Dr. Helen Thackray, the chief research and development officer, announced her departure from BioCryst to pursue a CEO role elsewhere. Thackray, who joined the board in 2019 and became the chief R&D officer in 2021, will transition to an advisory role until the end of the year. Her departure follows her participation as a finalist in the company’s recent CEO succession process. These developments reflect ongoing changes within the company’s leadership structure.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.